Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T22:51:46.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error rather than study details.
    Difference
    0.2%
    Check dated 2026-10-11T23:16:50.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page displays a 403 Forbidden message and a Home link in place of the study record content.
    Difference
    0.5%
    Check dated 2026-10-04T22:45:24.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error screen, replacing the study record content and navigation. The previous study details and related sections are no longer visible on this page.
    Difference
    19%
    Check dated 2026-09-20T22:16:33.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a new revision label (v3.6.6) replacing the previous v3.6.5, indicating a new build of the site. This reflects a maintenance/version update rather than substantive changes to study content or user-facing features.
    Difference
    0.1%
    Check dated 2026-08-30T15:42:10.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, indicating an updated site deployment. The previous Revision: v3.6.4 label has been superseded.
    Difference
    0.1%
    Check dated 2026-08-09T00:34:52.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.